People: Cypress Bioscience Inc (CYPB.O)

CYPB.O on Consolidated Issue listed on NASDAQ Global Market

5.06USD
9 Feb 2010
Price Change (% chg)

$0.08 (+1.61%)
Prev Close
$5.06
Open
--
Day's High
$5.10
Day's Low
$4.96
Volume
237,423
Avg. Vol
299,624
52-wk High
$9.95
52-wk Low
$4.91

view people for:

Summary

Name Age Since Current Position
Kranzler, Jay 51 1998 Chairman of the Board, Chief Executive Officer
Johnson, Sabrina 43 2008 Chief Financial Officer, Chief Operating Officer, Executive Vice President
Walsh, Michael 49 2008 Executive Vice President, Chief Compliance Officer
Gendreau, R. Michael 53 2006 Vice President - Clinical Development and Chief Medical Officer
Rao, Srinivas 40 2001 Chief Scientific Officer, Director of Science and Technology
Wheeler, Denise 39 2007 General Counsel
Millon, Jean-Pierre 58 2006 Lead Director
McGarity, Jon 67 2004 Director
Molinoff, Perry 69 2004 Director
Petree, Daniel 53 2004 Director
Hawley, Roger 56 2007 Director
Nova, Tina 55 2007 Director
Kalali, Amir 43 2007 Director
» Insider Trading

Biographies

Name Description
Kranzler, Jay Jay D. Kranzler has been Chairman of the Board, Chief Executive Officer of Cypress Bioscience Inc. He was appointed as its Chief Executive Officer and Vice-Chairman in December 1995. In April 1998, Dr. Kranzler was appointed as Chairman of the Board. From January 1989 until August 1995, Dr. Kranzler served as President, Chief Executive Officer and a director of Cytel Corporation, a publicly held biotechnology company. Dr. Kranzler is currently a lecturer at The Rady School of Business of the University of California-San Diego, where he serves as Executive in Residence. Before joining Cytel, from 1985 to January 1989, Dr. Kranzler was employed by McKinsey & Company, a management-consulting firm, as a consultant specializing in the pharmaceutical industry. Dr. Kranzler has an M.D. with a concentration in psychiatry and a Ph.D. in pharmacology from Yale University. He graduated summa cum laude from Yeshiva University.
Johnson, Sabrina Ms. Johnson was appointed as Executive Vice President, Chief Operating Officer and Chief Financial Officer of Cypress Bioscience Inc. In April 2005, she was promoted to Senior Vice President. In February 2006, she was promoted to Executive Vice President and Chief Business Officer and in January 2008 was appointed as Chief Operating Officer of the Company. Mrs. Johnson served as Vice President of Marketing from March 2001 to April 2002. Mrs. Johnson joined the Company in August of 1998 and held various positions from 1998 through 2000, including Product Director, Executive Director of Marketing and Sales, and Vice President of Marketing and Sales. From 1993 to 1998, Mrs. Johnson held marketing and sales positions with Advanced Tissue Sciences and Clonetics. Mrs. Johnson began her career in the biotechnology industry in 1990 as a research scientist with Baxter Healthcare, Hyland Division. Mrs. Johnson has an MBA from the American Graduate School of International Management (Thunderbird), a MSc. in Biochemical Engineering from the University of London and a BSc. in Biomedical Engineering from Tulane University.
Walsh, Michael Mr. Walsh has been Executive Vice President and Chief Commercial Officer of Cypress Bioscience Inc since March 2008. Prior to Cypress, Mr. Walsh founded Proprius Pharmaceuticals, Inc. in 2005 and was its President and CEO from its founding until the Company acquired Proprius in March 2008. Prior to establishing Proprius, Mr. Walsh was a founder and Executive Chairman at Prometheus Laboratories, Inc., a specialty pharmaceutical company, from 1995 to 2005. Prior to founding Prometheus Laboratories, Inc., Mr. Walsh was with Quidel Corporation in various senior executive roles, including Director of Worldwide Marketing and Business Development, and Director of European Operations. Prior to Quidel he was Manager of Therapeutic Operations at La Jolla Pharmaceutical Company. Mr. Walsh serves on the Board of Directors of Kanisa Pharmaceuticals, Inc., and as Chairman of the Board of Oculir, Inc. Mr. Walsh has a Bachelor of Science degree from the University of Notre Dame and an M.B.A. from Pepperdine University.
Gendreau, R. Michael Dr. Gendreau, M.D., Ph.D., has been Vice President - Clinical Development and Chief Medical Officer of Cypress Bioscience Inc. He was appointed as Vice President of Research and Development and Chief Medical Officer of Cypress Bioscience, Inc. in December 1996 and is currently serving as Vice President of Clinical Development and Chief Medical Officer. Dr. Gendreau joined Cypress Bioscience, Inc. in 1994 and held various positions from 1994 through 1996, including Executive Director of Scientific Affairs. From 1991 to 1994, Dr. Gendreau was Vice President of Research and Development and Chief Medical Officer for MicroProbe Corporation, a developer and manufacturer of DNA probe-based diagnostic equipment. Dr. Gendreau has a B.S. in chemistry from Ohio University and an M.D./Ph.D. in medicine and pharmacology from the Ohio State University.
Rao, Srinivas Mr. Rao is Chief Scientific Officer of Cypress Bioscience Inc. Dr. Rao joined the Company in August 2000, becoming Chief Scientific Officer in January 2001, and has worked in a variety of areas, including scientific assessment of potential in-licensing compounds, business development, preclinical study design, and development of Cypress’ intellectual property programs. Prior to Cypress, Dr. Rao worked as a free-lance medical electronics consultant while completing his combined M.D. and Ph.D. program at Yale Medical School. His Ph.D. research focused upon central nervous system neuropharmacology and took place in the laboratory of Dr. Patricia Goldman-Rakic. Upon completion of the M.D. degree, Dr. Rao completed an internship in Internal Medicine at Yale-New Haven Hospital. Dr. Rao holds both an M.S. and B.S. from Yale University in Electrical Engineering.
Wheeler, Denise Denise Wheeler is General Counsel of Cypress Bioscience Inc. Mrs. Wheeler was appointed as Vice President of Business and Legal Affairs and Corporate Secretary in February 2004 and in August 2006, assumed a part time role as Vice President of Legal Affairs, Corporate Secretary, and in October 2007 was appointed General Counsel. Prior to joining the Company, from September 1997 until January 2004, Mrs. Wheeler worked as a corporate attorney at the law firm of Cooley Godward LLP. Mrs. Wheeler has a B.A. from Old Dominion University and a J.D. from the University of San Diego, School of Law.
Millon, Jean-Pierre Jean-Pierre Millon has served as a Director of Cypress Bioscience, Inc. since March 2004 and Lead Director since April 2006. Mr. Millon is a Board member of the following companies, CVS/Caremark Corp., a pharmacy services company and INFUSYSTEM HOLDINGS, a healthcare company involved in infusion therapy. Mr. Millon joined the CVS/Caremark Board in March 2007 as a result of the acquisition of Caremark Rx by CVS, which had previously been acquired in March 2004 by Advance PCS. Mr. Millon joined PCS Health Systems, Inc. in 1995, where he served as its President and Chief Executive Officer from June 1996 to September 2000. Prior to joining PCS Health Systems, Mr. Millon served as an executive and held several leadership positions with Eli Lilly and Company, the former parent company of PCS Health Systems, Inc.
McGarity, Jon Jon W. McGarity has served as a Director of Cypress Bioscience, Inc. since March 2004. Mr. McGarity is the President and Chief Executive Officer of EthiX Associates, which he founded in 1996 and which is a company that provides executive consulting services in pharmaceutical/biotech/healthcare business planning, strategy and development. In addition, Mr. McGarity is the President & CEO of GenBioPro, Inc., a specialty biopharmaceutical company. Prior to establishing EthiX Associates, Mr. McGarity was the Vice Chairman, President and Chief Operating Officer of Pharmaceutical Marketing Services, Inc., which provided marketing and information services to the global pharmaceutical/healthcare industry. From February 2007 until March 2008, Mr. McGarity was the President and Chief Executive Officer of Insys Therapeutics, Inc., a privately held specialty pharmaceutical company. Mr. McGarity is the immediate past President and Chief Executive Officer of the Arizona BioIndustry Association. He is also a member of the Board of the Global Advisory Council at Thunderbird, The Garvin School of International Management and serves on the Board of Directors of the Arizona BioIndustry Association, the Board of Directors of the Arizona Technology Council, the Masters Level Computational Biosciences Degree Program and the Technopolis Program at Arizona State University.
Molinoff, Perry Dr. Molinoff has served as a Director of Cypress Bioscience, Inc. since September 2004. Dr. Molinoff is a neuropharmacologist with an M.D. from Harvard. He holds a faculty position in the Department of Pharmacology and was the A.N. Richards Professor of Pharmacology at the University of Pennsylvania and from November 2003 to July 2006 was the Vice Provost for Research at the University of Pennsylvania. He is also an Adjunct Professor of Physiology and Neuroscience at the Medical University of South Carolina, Charleston, SC. In addition to his faculty appointments, from January 1995 until March 2001, Dr. Molinoff was the Vice President – Neuroscience and Genitourinary Drug Discovery at Bristol-Myers Squibb Pharmaceutical Research Institute, where he was responsible for implementing and directing the Institute’s research efforts in multiple therapeutic areas. From September 2001 until November 2003, Dr. Molinoff served as Executive Vice President of Research and Development at Palatin Technologies, where he was responsible for all basic, preclinical and clinical research. Dr. Molinoff has been a member of the Board of Directors of Palatin Technologies since November 2001. He is a member of multiple editorial advisory boards for scientific and educational journals and has authored or edited 6 books including Basic Neurochemistry and Goodman and Gilman’s text, The Pharmacological Basis of Therapeutics, as well as over 225 manuscripts.
Petree, Daniel Daniel H. Petree has served as a Director of Cypress Bioscience, Inc. since June 2004. Mr. Petree is a founder and member of P2 Partners, LLC, a boutique investment bank specializing in life sciences companies, which he co-founded in 2000. From 1998 to 1999, Mr. Petree was the President and Chief Operating Officer of Axys Pharmaceuticals, a structure-based drug design company based in South San Francisco. From 1993 to 1998, he also held successive positions at Axys (and its predecessor, Arris Pharmaceuticals) as Executive Vice President of Business Development and Chief Financial Officer. From 1992 to 1993, Mr. Petree was Vice President of Business Development at TSI Corporation, a clinical research organization in Worcester, MA. Mr. Petree’s operating management experience was preceded by five years in investment banking at Montgomery Securities. Mr. Petree is also a member of the Board of Directors of Lpath, Inc., a public-traded biotechnology company. He also practiced as a corporate and securities lawyer with Heller, Ehrman, White & McAuliffe in Palo Alto, CA.
Hawley, Roger Roger L. Hawley has served as a Director of Cypress Bioscience, Inc. since April 26, 2007. Since February 2006, Mr. Hawley has served as chief executive officer and a director of Zogenix, Inc., a privately-held specialty pharmaceutical company. From 2003 until January 2006, Mr. Hawley served as executive vice president, commercial and technical operations of InterMune, Inc, a publicly-held biopharmaceutical company. From 2002 to 2003, Mr. Hawley served as chief commercial officer at Prometheus Laboratories, Inc., a specialty pharmaceutical company. From 2001 to 2002, Mr. Hawley served as vice president/general manager of sales and marketing at Elan Pharmaceuticals, Inc., a publicly-held biopharmaceutical company. From 1987 to 2001, Mr. Hawley held various management positions in corporate finance, sales, and marketing at GlaxoSmithKline, Inc. Prior to joining GlaxoSmithKline, Mr. Hawley spent 12 years in financial management with Marathon Oil Company. Mr. Hawley also serves as a director of Targeted Genetics Corporation, a publicly-traded clinical-stage biotechnology company. Mr. Hawley holds a B.S. in accounting from Eastern Illinois University.
Nova, Tina Tina S. Nova, Ph.D., has served as a Director of Cypress Bioscience, Inc. since April 26, 2007. Dr. Nova is a co-founder of Genoptix, Inc., a provider of personalized medicine services, and has served as its President and Chief Executive Officer and as a member of its board of directors since March 2000. Dr. Nova was a co-founder of Nanogen, Inc., a provider of molecular diagnostic tests, where she served as Chief Operating Officer and President from 1994 to January 2000. From 1992 to 1994, Dr. Nova served as Chief Operating Officer of Selective Genetics, a targeted therapy, biotechnology company. From 1988 to 1992, Dr. Nova held various director-level positions with Ligand Pharmaceuticals Incorporated, a drug discovery and development company, most recently serving as Executive Director of New Leads Discovery. Dr. Nova has also held various research and management positions with Hybritech, Inc., a former subsidiary of Eli Lilly & Company, a pharmaceutical company. Dr. Nova is a former life science sector representative to the Independent Citizen’s Oversight Committee overseeing the implementation of the California stem cell initiative, Proposition 71. Dr. Nova also serves on the board of directors of Arena Pharmaceuticals, Inc., a publicly traded clinical-stage biopharmaceutical company. Dr. Nova holds a B.S. in Biological Sciences from the University of California, Irvine and a Ph.D. in Biochemistry from the University of California, Riverside.
Kalali, Amir Dr. Amir Kalali serves as the Director of the Cypress Bioscience Inc on June 14, 2007. Dr. Kalali is currently Vice President, Medical and Scientific Services, and Global Therapeutic Team Leader CNS, at Quintiles Inc., focusing on developing novel compounds for the treatment of disorders of the central nervous system. He is globally responsible for the medical and scientific aspects of development programs in psychiatry and neurology. He is also Professor of Psychiatry at University of California San Diego. He was the Founding Chairman of the Executive Committee of the International Society for CNS Drug Development (ISCDD), and currently the Executive Secretary. Dr. Kalali received his M.D. from the University of London, United Kingdom. He completed his psychiatry training at University College and Middlesex School of Medicine, London University. Dr. Kalali has been an academic investigator in over 70 psychopharmacological clinical trials and at Quintiles has had medical and scientific responsibility for over 150 clinical trials. Dr. Kalali regularly presents at national and international scientific meetings, and lectures frequently on psychopharmacological and drug development topics. Dr. Kalali is the Editor of the journal Psychiatry, and is on the editorial board of several other journals. He has published widely in journals such as the Archives of General Psychiatry, The American Journal of Psychiatry, and the British Journal of Psychiatry. Dr. Kalali is an active member of the Scientific Advisory Boards of many pharmaceutical companies and sits on the Board of Directors of the Neuroscience Education Institute and Tikvah Therapeutics. In 2005 and 2006 PharmaVOICE magazine named Dr. Kalali as one its 100 most inspiring leaders in the life sciences.

Basic Compensation

Name Fiscal Year Total
Kranzler, Jay 3,610,730
Johnson, Sabrina 795,551
Walsh, Michael 853,200
Gendreau, R. Michael 685,516
Rao, Srinivas 555,006
Wheeler, Denise 582,458
Millon, Jean-Pierre --
McGarity, Jon --
Molinoff, Perry --
Petree, Daniel --
Hawley, Roger --
Nova, Tina --
Kalali, Amir --
As Of 30 Dec 2008

Options Compensation

Name Options Value
Kranzler, Jay 1,981,893 3,759,057
Johnson, Sabrina 176,003 559,202
Walsh, Michael 0 0
Gendreau, R. Michael 294,855 1,740,099
Rao, Srinivas 0 0
Wheeler, Denise 53,216 71,784
Millon, Jean-Pierre 0 0
McGarity, Jon 0 0
Molinoff, Perry 0 0
Petree, Daniel 0 0
Hawley, Roger 0 0
Nova, Tina 0 0
Kalali, Amir 0 0

Insider Trading

Name Shares Traded Price
KRANZLER JAY D 100,000 $0.00
WALSH MICHAEL 5,000 $6.00
KRANZLER JAY D 75,000 $8.69
KRANZLER JAY D 75,000 $2.51
KRANZLER JAY D 75,000 $2.51
KRANZLER JAY D 75,000 $8.70
KRANZLER JAY D 75,000 $8.19
KRANZLER JAY D 75,000 $2.51
KRANZLER JAY D 1,800 $8.60
KRANZLER JAY D 2,000 $8.57
KRANZLER JAY D 2,000 $8.62
KRANZLER JAY D 5,000 $8.50
KRANZLER JAY D 300 $8.67
KRANZLER JAY D 2,000 $8.57
KRANZLER JAY D 2,000 $8.59
KRANZLER JAY D 2,000 $8.60
KRANZLER JAY D 5,000 $8.63
KRANZLER JAY D 1,000 $8.53
KRANZLER JAY D 4,000 $8.58
KRANZLER JAY D 2,000 $8.60
KRANZLER JAY D 2,000 $8.62
KRANZLER JAY D 60,094 $2.51
KRANZLER JAY D 10,000 $8.65
KRANZLER JAY D 2,200 $8.55
KRANZLER JAY D 2,000 $8.59
» Full list on Insider Trading
view people for: